Skip to content

Debt-to-equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
0.7×0.0×
Merck & Co. logo
Merck & Co.MRK
1.1×+0.3×
CG Oncology logo
CG OncologyCGON
0.0×
Arvinas logo
ArvinasARVN
0.0×
Replimune Group logo
Replimune GroupREPL
0.4×+0.2×
Immunome logo
ImmunomeIMNM
0.0×

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Current ratio18.3×+13.0×

Where this comes from

Calculated from Relmada Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s debt-to-equity?
Relmada Therapeutics, Inc. (RLMD) reported debt-to-equity of 0.9× in Q2 2023.
How has Relmada Therapeutics, Inc.'s debt-to-equity changed year-over-year?
Relmada Therapeutics, Inc.'s debt-to-equity increased by 5.3% year-over-year, from 0.9× to 0.9×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.